Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 11/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.32 |
| ▸ | TNF | P01375 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.31 |
| ▸ | PI4KA | P42356 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14243224 | 0.81 | NOS3 (0.43) | PTGS2PIK3CDPIP5K1CPIK3CBPI4KA | |
| SCHEMBL14242832 | 0.77 | NOS3 (0.35) | PTGS2NR1H2NR1H3PIK3CDPIP5K1C | |
| SCHEMBL14242844 | 0.77 | FEN1 (0.38) | ABL1 | |
| SCHEMBL17703500 | 0.76 | FYN (0.33) | PTGS2PIK3CDPIP5K1CPIK3CBPI4KA | |
| SCHEMBL12549572 | 0.76 | PIK3CD (0.31) | PIK3CDPIP5K1CPIK3CBPI4KAPIK3CG | |
| SCHEMBL18594441 | 0.74 | NOS3 (0.40) | PIK3CDPIP5K1CPIK3CBPI4KAPIK3CG | |
| SCHEMBL1458885 | 0.72 | GAA (0.32) | ABL1PIK3CDPIP5K1CPIK3CBPI4KA | |
| SCHEMBL19931370 | 0.72 | GPR119 (0.33) | PTGS2PIK3CDPIP5K1CPIK3CBPI4KA | |
| SCHEMBL3257964 | 0.72 | UHRF1 (0.52) | PIK3CDPIP5K1CPIK3CBPI4KAPIK3CG | |
| SCHEMBL27935057 | 0.72 | PIK3CD (0.31) | PIK3CDPIP5K1CPIK3CBPI4KAPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170342089-A1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2017-11-30 | — | — | US | disclosed |
| US-20170342089-A1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2017-11-30 | — | — | US | disclosed |
| US-9777018-B2 | Compounds as modulators of GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2017-10-03 | — | — | US | disclosed |
| US-9777018-B2 | Compounds as modulators of GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2017-10-03 | — | — | US | disclosed |
| EP-2718279-B1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2016-08-10 | — | — | EP | disclosed |
| US-20150361092-A1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2015-12-17 | — | — | US | disclosed |
| US-20150361092-A1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2015-12-17 | — | — | US | disclosed |
| US-9181214-B2 | Bicyclic compounds as modulators of GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2015-11-10 | — | — | US | disclosed |
| US-9181214-B2 | Bicyclic compounds as modulators of GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2015-11-10 | — | — | US | disclosed |
| US-20130045986-A1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2013-02-21 | — | — | US | disclosed |
| US-20130045986-A1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2013-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361092-A1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | GPR119, GPR39, GPBAR1 | PTGS2 571/4885NR1H2 28/4885NR1H3 36/4885 |
| US-20130045986-A1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | GPR119, GPR39, GPBAR1 | PTGS2 571/4885NR1H2 28/4885NR1H3 36/4885 |
| US-20170342089-A1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | GPR119, GPR39, GPBAR1 | PTGS2 571/4885NR1H2 28/4885NR1H3 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.